title: Administration of filgrastim in two patients with drug-induced agranulocytosis.
abstract: Two patients experienced agranulocytosis associated with either procainamide or trimethoprim-sulfamethoxazole. Both were treated with filgrastim in an attempt to decrease the duration of agranulocytosis. The first patient received 12 days and the second patient 4 days of filgrastim before white blood cell counts recovered. Published reports both support and refute the efficacy of filgrastim in this setting. The agent may be beneficial in certain cases of this disorder, but further investigation is necessary to determine if it has a definitive role.
authors.affiliation: University of Pittsburgh Cancer Institute, Pennsylvania, USA.
authors.forename: D
authors.initials: D
authors.lastname: Castanheira
authors.forename: M
authors.initials: M
authors.lastname: Marzella
authors.forename: J A
authors.initials: JA
authors.lastname: Skirvin
mesh_terms: D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced / Q000188:drug therapy*; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects; D000890:Anti-Infective Agents / Q000009:adverse effects; D064420:Drug-Related Side Effects and Adverse Reactions; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011342:Procainamide / Q000009:adverse effects; D011994:Recombinant Proteins; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects
chemical_list: D000889:Anti-Arrhythmia Agents; D000890:Anti-Infective Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D011342:Procainamide; D000069585:Filgrastim